Abstract: Provided herein are compounds and methods for gene silencing. The compound includes a RNA directly conjugated to an albumin-binding group. The method includes administering a compound comprising a RNA directly conjugated to an albumin-binding group to a subject in need thereof.

Abstract: Disclosed herein are drug coated medical devices that can be used for the treatment of vascular diseases. An example device includes a medical device having an outer surface, and a multi-layer drug coating on the outer surface, the multi-layer drug coating including at least one polycationic layer including a cationic therapeutic and at least one polyanionic layer including an anionic polymer. Also disclosed are methods of making the drug coated medical devices and methods of treating vascular diseases.

Abstract: Provided herein are compounds and methods for gene silencing. The compound includes a RNA directly conjugated to an albumin-binding group. The method includes administering a compound comprising a RNA directly conjugated to an albumin-binding group to a subject in need thereof.

Abstract: Disclosed herein are methods of treating central nervous system diseases, such as Alzheimer's disease and Huntington's disease, using lipophilic siRNA conjugates that can bind to albumin. The disclosed methods can advantageously provide widespread, long-term gene silencing in the central nervous system. An example method includes administering to a subject an effective amount of a conjugate, optionally in combination with a pharmaceutically acceptable excipient, wherein the conjugate includes a siRNA capable of inhibiting expression of a protein associated with the central nervous system disease; a lipophilic ligand capable of binding albumin; and a linker attaching the siRNA to the lipophilic ligand, the linker including a branching molecule attached to the siRNA, and a hydrophilic spacer attaching the branching molecule to the lipophilic ligand.

Abstract: Disclosed herein arm block copolymers that have beneficial drug loading properties. An example block copolymer includes a first block that is hydrophilic and a second block having pendant groups that can non-covalently interact with a drug. Also disclosed are particles including self-assembled block copolymers and a drug; and methods of treating diseases.

Abstract: Disclosed herein are methods of treating inflammatory diseases, such as arthritis or traumatic injury, using lipophilic siRNA conjugates that can bind to albumin. An example method includes administering to a subject an effective amount of a conjugate, optionally in combination with a pharmaceutically acceptable excipient, wherein the conjugate includes a siRNA capable of inhibiting expression of a protein associated with the inflammatory disease; a lipophilic ligand capable of binding albumin; and a linker attaching the siRNA to the lipophilic ligand, the linker including a branching molecule attached to the siRNA, and a hydrophilic spacer attaching the branching molecule to the lipophilic ligand.

Abstract: The presently-disclosed subject matter includes hydrophilic thioketal polymers and scaffolds formed therefrom.

Abstract: The disclosure describes engineered cells for the treatment of joint and bone disease. The cells are engineered to sense signals only found in diseased compartments and in turn produce therapeutic molecules that are secreted into the local environment.

Abstract: Provided herein are micellic assemblies comprising a plurality of copolymers. In certain instauces, micellic assemblies provided herein are pH sensitive particles.

Abstract: Provided herein are compounds and methods for gene silencing. The compound includes a RNA directly conjugated to an albumin-binding group. The method includes administering a compound comprising a RNA directly conjugated to an albumin-binding group to a subject in need thereof.

Abstract: The present disclosure relates to probes and methods for detecting nucleic acids, and for detecting and treating neovas-cularization.

Abstract: Provided herein are compounds and methods for gene silencing. The compound includes a RNA directly conjugated to an albumin-binding group. The method includes administering a compound comprising a RNA directly conjugated to an albumin-binding group to a subject in need thereof.

Abstract: A polymeric nanocarrier and method of treating a bone disease are provided. The polymeric nanocarrier includes an amphiphilic copolymer including a hydrophobic block and a hydrophilic block, where the hydrophilic block comprises a random copolymer. The method of treating a bone disease includes administering the polymeric nanocarrier to a subject in need thereof.

Abstract: Provided herein are a reactive oxygen species (ROS) scavenging composition, a method of forming a ROS scavenging composition, and a method of treating a subject having a (ROS) perpetuated disease. The ROS scavenging composition includes a co-polymer of a hydrophilic monomer and a grafting monomer, and a ROS scavenging compound grafted to the grafting monomer. The method of forming a ROS scavenging composition includes forming a co-polymer of a hydrophilic monomer and a grafting monomer, and grafting ROS scavenging compound onto the co-polymer. The method of treating a subject having a ROS perpetuated disease includes administering a therapeutically effective amount of an ROS scavenging composition comprising a co-polymer of a hydrophilic monomer and a grafting monomer, and a ROS scavenging compound grafted to the grafting monomer, to the subject in need thereof.

Abstract: A reactive oxygen species savaging emulsion; the emulsion comprising an injectable pharmaceutically acceptable composition and a polymeric poly(propylene sulfide) microsphere for targeted delivery to a site with elevated reactive oxygen species. In embodiments of the present invention, the microsphere is loaded with a biologically active agent.

Abstract: Provided herein are a polymer, a polyplex, and a method of treating a disease. The polymer includes a core-forming block and a zwitterionic corona block. The polyplex includes the polymer complexed with an active agent. The method of treating a disease comprises administering the polyplex to a subject in need thereof.

Abstract: Provided herein are micellic assemblies comprising a plurality of copolymers. In certain instances, micellic assemblies provided herein are pH sensitive particles.

Abstract: The presently-disclosed subject matter includes a polymer (i.e., copolymer) comprising a thermally responsive block and a hydrophobic block. In some embodiments the copolymer is a terpolymer. Specific embodiments include a thermo-responsive, ROS degradable ABC triblock terpolymer comprising poly(propylenesulfide)-block-poly(N,N-dimethylacrylamide)-block-poly(N-isopropylacrylamide) (PPS-b-PDMA-b-PNIPAAM).

Abstract: Embodiments of the present disclosure include particles, methods of making particles, methods of delivering an active agent using the particle, and the like.

Abstract: Provided herein are micellic assemblies comprising a plurality of copolymers. In certain instauces, micellic assemblies provided herein are pH sensitive particles.